Emerging Markets Earnings Roundup: Eli Lilly, Roche (Part 4)
This article was originally published in PharmAsia News
Executive Summary
Eli Lilly says emerging markets remain a growing focus as it navigates sliding sales for key products in developed markets due to patent expirations. Roche looks to patient access programs again as biosimilar competition threats grow.